MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
Why Hong Kong's carried interest reform matters, and why it isn't a zero-sum play
Medical centre expansion in Hong Kong: How to choose the right location
The Claude ban is a crash course in digital resilience — and that’s good for Hong Kong bankers